A 52-year-old man with known cirrhosis (Child-Pugh Class C) presents with hematemesis and melena. Vital signs show BP 90/50 mmHg, HR 120/min. Hemoglobin is 7.8 g/dL. PT is 18 seconds (INR 2.2), aPTT 48 seconds, platelet count 65,000/μL, and fibrinogen 140 mg/dL. Endoscopy confirms active variceal bleeding. What is the most appropriate immediate management?

Explanation

## Clinical Context: Variceal Hemorrhage in Cirrhosis **Key Point:** Variceal bleeding in cirrhosis is a medical emergency with high mortality. Management requires simultaneous hemodynamic resuscitation, pharmacological vasoconstriction, infection prophylaxis, and endoscopic hemostasis. ## Pathophysiology of Coagulopathy in Cirrhosis Liver disease causes: - Reduced synthesis of clotting factors (II, V, VII, IX, X) - Thrombocytopenia (from splenomegaly and bone marrow suppression) - Reduced fibrinogen and impaired fibrinolysis - **Result:** Complex coagulopathy that does NOT respond well to isolated FFP or vitamin K ## Immediate Management Strategy ### 1. Hemodynamic Resuscitation **High-Yield:** Restrictive transfusion strategy is preferred in variceal bleeding: - Target hemoglobin **8–9 g/dL** (NOT 10–12 g/dL) - Rationale: Aggressive transfusion increases portal pressure and worsens rebleeding - Use **packed RBCs** (not FFP alone) to avoid fluid overload ### 2. Vasoactive Agents **Clinical Pearl:** Must be started BEFORE or at the time of endoscopy and continued for 2–5 days: | Agent | Mechanism | Onset | Preferred in | | --- | --- | --- | --- | | **Terlipressin** | V1 receptor agonist; splanchnic vasoconstriction | 30 min | Preferred (most evidence) | | **Octreotide** | Somatostatin analog; reduces portal pressure | 15 min | Alternative; less effective than terlipressin | | **Propranolol** | β-blocker; reduces portal flow | Hours | Chronic prophylaxis, not acute | ### 3. Infection Prophylaxis **Key Point:** Bacterial infection occurs in 30–50% of variceal bleeding. Prophylactic antibiotics reduce mortality: - **Ceftriaxone 1 g IV/IM daily** (preferred) or - **Norfloxacin 400 mg BD** (for low-risk patients) - Duration: 7 days ### 4. Endoscopic Therapy - **EVL (endoscopic variceal ligation)** is superior to sclerotherapy (lower rebleeding, mortality) - Perform after initial resuscitation and vasoactive agent initiation ### 5. Coagulopathy Management **Warning:** FFP and vitamin K are NOT first-line: - **FFP** is transient (6–8 hours) and causes fluid overload; reserve for severe coagulopathy (INR >2.5) with active bleeding after EVL failure - **Vitamin K** is ineffective in cirrhosis (impaired hepatic synthesis, not just deficiency) - **Platelet transfusion** is NOT routinely indicated unless count <50,000/μL with active bleeding ## Management Algorithm ```mermaid flowchart TD A[Variceal bleeding + hemodynamic instability]:::outcome --> B[IV access, type & cross]:::action B --> C[Packed RBC: target Hb 8-9 g/dL]:::action C --> D[Start vasoactive agent: terlipressin or octreotide]:::action D --> E[Prophylactic antibiotics: ceftriaxone]:::action E --> F[Urgent endoscopy for EVL]:::action F --> G{Hemostasis achieved?}:::decision G -->|Yes| H[Continue vasoactive agent 2-5 days]:::action G -->|No| I{Severe coagulopathy?}:::decision I -->|Yes| J[FFP + repeat EVL or TIPS]:::action I -->|No| K[Repeat EVL or TIPS]:::action H --> L[Discharge planning + beta-blocker]:::outcome ``` **Mnemonic:** **BEAT** — **B**lood (restrictive), **E**ndoscopy (EVL), **A**ntibiotics, **T**erlipressin/vasoactive.